Chhattisgarh Health Minister T S Singh Deo said he had written to Harsh Vardhan urging him not to send Bharat Biotech s Covaxin till the phase-3 clinical trial results are completed.
Allaying concerns of Chhattisgarh over incomplete phase 3 trials of Covaxin, Union Health Minister Harsh Vardhan on Thursday said both this and the other COVID-19 vaccine Covishield are safe and immunogenic and should be used expeditiously to mitigate the impact of the pandemic.
India News: NEW DELHI: Allaying concerns of Chhattisgarh over incomplete phase 3 trials of Covaxin, Union health minister Harsh Vardhan on Thursday said both this.
Vaccines approved! SII, Bharat Biotech get DCGI nod for restricted use in emergency situation
SII Pune has submitted safety immunogenicity and efficacy data generated on 23,745 participants, The overall vaccine efficacy was found to be 70.42 per cent.
Share Via Email
| A+A A-
DGCI has accepted the govt panel s recommendation to grant restricted emergency use authorization to Covishield, Covaxin.
Express News Service
NEW DELHI: V G Somani, Drug Controller General of India (DCGI) on Sunday announced that the recommendations of a government-appointed panel to grant restricted emergency use authorization to Covid-19 vaccines by Serum Institute of India and Bharat Biotech in the country are being accepted.
Covishield, Covaxin approved
Both vaccines to be administered in two doses
Can be stored in normal refrigerator
New Delhi: It is indeed a red-letter day for India today as two vaccines for
COVID-19 produced by Pune-based Serum Institute’s Covishield and Bharat Biotech’s Covaxin, received emergency approval from the country’s drug regulator this morning.
Drug Controller General of India (DCGI) V.G. Somani said both firms submitted data on their trial runs and both have been granted permission for “restricted use.” “We’ll never approve anything if there is slightest of safety concern. The vaccines are 110 percent safe. Some side effects like mild fever, pain and allergy are common for every vaccine,” Somani said, addressing a news conference in New Delhi.